UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043673
Receipt number R000049863
Scientific Title A Study on Lipid Improvement Effect of Food Containing Plant Extract -A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-
Date of disclosure of the study information 2021/03/19
Last modified on 2022/03/01 11:16:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on Lipid Improvement Effect of Food Containing Plant Extract
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-

Acronym

A Study on Lipid Improvement Effect of Food Containing Plant Extract

Scientific Title

A Study on Lipid Improvement Effect of Food Containing Plant Extract
-A Randomized, Double-blind, Placebo-controlled, Parallel-group Study-

Scientific Title:Acronym

A Study on Lipid Improvement Effect of Food Containing Plant Extract

Region

Japan


Condition

Condition

No

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm the lipid improvement effect of food containing plant extract

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

LDL-cholesterol
Triglyceride

Key secondary outcomes

Other lipid metabolism markers
Body fat and liver function markers


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Foods containing plant extract, 12 weeks consumption

Interventions/Control_2

Foods not containing plant extract, 12 weeks consumption

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Healthy males and females aged 20 to 64 years-old.
(2) Subjects whose LDL-cholesterol levels are 139 mg/dL or less, or triglyceride levels are 149 mg/dL or less by the screening tests.
(3) Subjects whose HDL-cholesterol levels are 40 mg/dL or over.
(4) Subjects whose BMI are under 30.
(5) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1) Subjects who use medications affecting obesity, hyperlipidemia, lipid metabolism.
(2) Subjects who contract or are under treatment for serious diseases (e.g., liver disease, kidney disease, digestive disease, heart disease, respiratory disease, endocrine disease, thyroid disease, adrenal disease and/or metabolic disease).
(3) Subjects who can't stop using supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting obesity, hyperlipidemia, lipid metabolism.
(4) Subjects with tendency of diarrhea or who have diarrhea within 2 weeks before the screening test.
(5) Subjects who are shift workers and/or night-shift workers.
(6) Subjects who were pregnant or planned to become pregnant or breastfeed during the study period.
(7) Subjects who have been diagnosed as familial hyperlipidemia.
(8) Subjects with a history of and/or current drug addiction and/or alcoholism.
(9) Subjects who were planning to participate and/or had participated in other clinical studies within the month prior to the commencement of the current study.
(10) Subjects who were judged as unsuitable for the current study by the investigator for other reasons.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Masahiko
Middle name
Last name Tokushima

Organization

Maebashi North Hospital

Division name

Director

Zip code

371-0054

Address

692 Shimohosoi-machi,Maebashi-shi,Gunma

TEL

027-235-3333

Email

sagawa@mc-connect.co.jp


Public contact

Name of contact person

1st name Yoshika
Middle name
Last name Komori

Organization

KSO Corporation

Division name

Sales department

Zip code

105-0023

Address

1-9-7 Shibaura, Minato-ku, Tokyo

TEL

03-3452-7733

Homepage URL


Email

eigyou27@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

TOYO SHINYAKU Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Kobuna Orthopedics Clinic

Address

5-656-17 Joto-machi, Maebashi-shi, Gunma

Tel

027-212-5608

Email

sagawa@mc-connect.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 19 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000049863

Publication of results

Published


Result

URL related to results and publications

http://www.pieronline.jp/content/article/0386-3603/50010/109

Number of participants that the trial has enrolled

80

Results

Statistically significant difference was confirmed in the primary outcome.

Results date posted

2022 Year 03 Month 01 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Males and females aged 20 to 64years old.

Participant flow

Enrolled(n=80)
Completed(n=79)
Analysed(n=64)

Adverse events

No adverse events were observed that be related to test food.

Outcome measures

LDL-cholesterol
Triglyceride

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2021 Year 03 Month 18 Day

Date of IRB

2021 Year 03 Month 18 Day

Anticipated trial start date

2021 Year 03 Month 22 Day

Last follow-up date

2021 Year 08 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 03 Month 19 Day

Last modified on

2022 Year 03 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049863


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name